Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma Clinical Trials

6 clinical trials for Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma — RECRUITING · PHASE1
• Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma — RECRUITING · PHASE1
• Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy — RECRUITING · PHASE2
• Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas — ACTIVE_NOT_RECRUITING · PHASE2
• Axatilimab + CAR-T for High-Risk Lymphoma — NOT_YET_RECRUITING · PHASE1
• NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1

Refine this search